Drug Profile
Natural killer cell therapy - Shenzhen Hank Bioengineering Institute
Alternative Names: HANK cell - Shenzhen Hank Bioengineering Institute; High-activity natural killer cells - Shenzhen Hank Bioengineering Institute; Natural killer immunotherapy - Shenzhen Hank Bioengineering InstituteLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator HANK Bioengineering
- Developer Fuda Cancer Hospital; HANK Bioengineering
- Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Breast cancer; Cervical cancer; Colorectal cancer; Laryngeal cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pharyngeal neoplasms; Renal cancer; Soft tissue sarcoma; Solid tumours; Tongue cancer
Most Recent Events
- 23 Feb 2022 No development reported - Phase-I/II for B-cell lymphoma (Combination therapy, Recurrent, Second-line therapy or greater) in China (IV)
- 23 Feb 2022 No development reported - Phase-I/II for Breast cancer (Combination therapy, Recurrent, Second-line therapy or greater) in China (IV)
- 23 Feb 2022 No development reported - Phase-I/II for Breast cancer (Late-stage disease, Monotherapy, Recurrent, Second-line therapy or greater, Adjuvant therapy) in China (IV)